In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure using a clip to repair the valve was safe, cut the rate of hospitalizations for heart failure by 47% and reduced deaths from any cause by almost 30% after five years of follow-up, according to a study presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.

The best surgical approach for mitral valve repair is subject to wide debate. Findings from the randomized UK Mini Mitral trial showed similar improvement in physical activity, surgical outcomes and quality of life in patients undergoing minimally invasive and conventional surgical techniques for mitral valve repair.

In patients with heart failure and severe secondary mitral regurgitation, mitral transcatheter edge-to-edge repair (TEER) was associated with lower rates of all hospitalizations, hospitalizations for cardiovascular causes, and hospitalizations for heart failure through 5-years of the COAPT trial.

Following TEER, there has been no significant improvement in 90-day readmission rates between 2012 and 2018. Female gender is associated with higher 90-day all-cause and heart failure readmission rates.

Built on the trusted Carpentier-Edwards PERIMOUNT valve platform, and made with RESILIA tissue for decreased calcification†, this is the mitral valve developed with your patient's quality of life in mind.

In the largest randomized trial conducted to compare minimally invasive and conventional cardiac surgical techniques for repairing a poorly functioning mitral valve, improvements in physical activity, as well as surgical outcomes and quality of life, were similar in both groups of patients at 12 weeks post-surgery. The research was presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology.

Overall, the five-year outcomes confirmed that TEER, previously known as transcatheter mitral valve repair, with the MitraClip device was associated with a reduction in heart failure hospitalizations and improved survival among patients presenting with severe secondary MR. The device was also linked to consistent MR reductions.

Transcatheter mitral valve repair for heart failure patients with mitral regurgitation can reduce the long-term rate of hospitalizations by almost 50 percent, and death by nearly 30 percent, compared with heart failure patients who don’t undergo the minimally invasive procedure.

QoL following TMVr is a powerful prognostic factor. KCCQ assessment is an important indicator for identifying patients prone to adverse outcomes even after procedural success.

Transcatheter edge-to-edge repair (TEER) is a minimally invasive procedure in which a catheter (a long flexible tube) is used to place a tiny clip in the mitral valve to help it close properly and prevent blood from leaking back into the left atrium. TEER is approved by the U.S. Food and Drug Administration for mitral valve repair in patients with severe isolated mitral valve regurgitation who, due to age or other health problems, are considered at high risk for complications from conventional mitral valve surgery.

Since CAD and AS often coexist, the evaluation and management of CAD in TAVI candidates is of paramount importance, particularly with the extension of the procedure to younger and lower-risk patients. Invasive coronary angiography remains the mainstay for CAD diagnosis, although CTCA might be considered for initial screening, particularly in patients at low risk for CAD. The role of coronary invasive physiology assessment needs to be further clarified. In patients undergoing TAVI, PCI should be performed in the setting of severe CAD with the involvement of proximal vessel segments or in patients with angina, preferably before THV implantation, and in particular if a THV with supra-annular leaflets is selected. The THV choice affects future coronary access after TAVI. Commissural alignment techniques should be routinely adopted to optimise coronary access.

Mitral valve disease can be caused by a number of factors and each person's valve may be affected differently. Some valve disease may be due to infection, rheumatic fever, heart attack, coronary artery disease or other causes.

We describe the case of a woman in her 60s with mitral stenosis, rate-controlled atrial fibrillation and a history of childhood rheumatic fever. She successfully underwent elective percutaneous transvenous mitral commissurotomy (PTMC), also described as balloon mitral valvuloplasty, for severe, symptomatic mitral stenosis. This was completed via right femoral vein access, trans-septal puncture and commissural separation guided by real-time three-dimensional (3D) transoesophageal echocardiography under general anaesthesia.

Coaptation length (CL) after surgical mitral valve repair (MVr) has been considered an independent predictor of recurrent mitral regurgitation (MR) in patients with functional MR1(Figure 1a and b). However, its role in degenerative MR has not been fully explored, and there is a scarcity of studies addressing this issue.

Mitral Valve Disease: Mitral valve is a type of heart disease that affect the left chambers of the heart. It allows blood to flow backward into the left atrium. This disease is also known as the bicuspid valve or left atrioventricular valve which involves two cusps or flaps that lie between the left ventricle and left atrium of the heart.

Secondary mitral regurgitation occurs due to an imbalance between closing forces and tethering forces. Given the pathology extends beyond the valve alone, treatment should be directed at restoring the geometrical shape of the left ventricle alongside the valve. Myocardial revascularization plays a pivotal role in preventing recurrence. The role of papillary muscle approximation in addition to restrictive mitral annuloplasty should be considered in a select group of patients.

‘iTrain’ is an interactive training course designed to support post-stroke care. It consists of a combination of different tools – a brochure, an interactive Massive Open Online Course (MOOC), visual material, and a serious game, which is becoming an increasingly popular form of training.

Mitral valve disease can be caused by a number of factors and each person's valve may be affected differently. Some valve disease may be due to infection, rheumatic fever, heart attack, coronary artery disease or other causes.

When the Mitral Valve Stenosis condition happens, pressure built up in the patient’s heart reaches his lungs. This causes fluid build-up in the lungs, thus causing congestion and gasping for breath. Mitral valve stenosis takes some time before it manifests itself. So you might be suffering for decades before the actual symptoms show. Here are the symptoms of Mitral valve stenosis.

Secondary mitral regurgitation (MR) refers to MR resulting from left ventricular or left atrial remodeling. In ischemic or nonischemic cardiomyopathy, left ventricular dilation (regional or global) leads to papillary muscle displacement, tethering, and leaflet malcoaptation. In atrial functional MR, MR occurs in patients with left atrial dilation and altered mitral annular geometry due to atrial fibrillation. In addition to cardiac remodeling, leaflet remodeling is increasingly recognized. Mitral leaflet tissue actively adapts through leaflet growth to ensure adequate coaptation. Leaflets, however, can also undergo maladaptive thickening and fibrosis, leading to increased stiffness.